Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Posted by Micah Haroldson on Feb 27th, 2026

Perrigo (NYSE:PRGO – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 2.250-2.550 for the period, compared to the consensus EPS estimate of 2.700. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.2 billion.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PRGO shares. Canaccord Genuity Group dropped their price target on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, November 6th. Argus upgraded shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. JPMorgan Chase & Co. cut their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Friday, February 13th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research report on Thursday. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.33.

Check Out Our Latest Stock Analysis on Perrigo

Perrigo Stock Performance

Shares of Perrigo stock opened at $14.18 on Friday. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -37.32, a PEG ratio of 1.29 and a beta of 0.39. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.51 and a quick ratio of 1.44. The firm’s 50-day moving average is $14.41 and its 200 day moving average is $17.55. Perrigo has a 1 year low of $12.17 and a 1 year high of $30.93.

Perrigo (NYSE:PRGO – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by ($0.03). The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 1.21% and a positive return on equity of 9.16%. Perrigo’s revenue was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts anticipate that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be paid a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.2%. The ex-dividend date is Monday, March 2nd. Perrigo’s dividend payout ratio (DPR) is -305.26%.

Perrigo News Summary

Here are the key news stories impacting Perrigo this week:

Positive Sentiment: Perrigo announced an operational enhancement program expected to deliver $80M–$100M of pre‑tax annualized savings, which could support margins over time. Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Positive Sentiment: Management said Perrigo Store Brand OTC and key branded products gained market share in 2025 despite soft category consumption, a supportive sign for organic recovery. Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Neutral Sentiment: Revenue of $1.11B slightly exceeded consensus (~$1.09B), but organic net sales were down ~4.5% year‑over‑year, showing mixed top‑line momentum. Perrigo Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Neutral Sentiment: Company is shifting to new reporting segments (aligned to commercial model) and introduced a “CORE” outlook that excludes infant formula and announced divestitures—useful for modelers but adds transitional complexity. Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Negative Sentiment: Earnings per share of $0.77 missed the consensus of $0.80 and declined from $0.93 a year ago, signaling margin pressure and weaker profitability. Perrigo Q4 Earnings Lag Estimates
Negative Sentiment: FY2026 “all‑in” EPS guidance of $2.25–$2.55 and revenue guidance of ~$4.0–$4.2B came in below Street expectations (consensus EPS ~2.70), which is the primary driver of downward pressure on the stock. Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Negative Sentiment: Analyst and investor reaction was sharp—coverage pieces flagged the miss and the weaker outlook, contributing to a significant intraday sell‑off. Why Perrigo Company plc’s (PRGO) Stock Is Down 7.46%

Institutional Trading of Perrigo

Several large investors have recently added to or reduced their stakes in PRGO. T. Rowe Price Investment Management Inc. boosted its stake in shares of Perrigo by 35.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock worth $19,295,000 after acquiring an additional 363,501 shares during the last quarter. Invesco Ltd. lifted its position in Perrigo by 134.2% during the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in Perrigo in the fourth quarter worth about $283,000. Vident Advisory LLC raised its stake in shares of Perrigo by 7.0% in the fourth quarter. Vident Advisory LLC now owns 51,098 shares of the company’s stock worth $711,000 after buying an additional 3,350 shares during the period. Finally, First Citizens Bank & Trust Co. lifted its position in shares of Perrigo by 126.3% during the 4th quarter. First Citizens Bank & Trust Co. now owns 39,207 shares of the company’s stock valued at $546,000 after buying an additional 21,884 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors.

Perrigo Company Profile

(Get Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.